FLT1/VEGFR1 is a vascular endothelial growth factor receptor and its ligands include VEGFA, VEGFB and PlGF. The anti-VEGFA drug bevacizumab is a standard treatment for metastatic CRC and is associated with a benefit in terms of overall survival. The gene discussed is FLT1; the disease is colorectal carcinoma.